Article
Author(s):
Top news of the day from across the healthcare landscape.
Pharmaceutical manufacturers and other healthcare stakeholders spent more than $2 million on events and contributions to the Trump administration. President Donald Trump’s inaugural committee was found to have raised more than $107 million—more than twice the amount of former President Barack Obama’s committee, which held the record at $53 million, according to Kaiser Health News. The authors of the article speculate that the high amount of spending may be the result of Trump vowing to reduce drug costs and allow the negotiation of Medicare drug costs.
A new study shows that aging mice brains may be rejuvenated by a protein found in umbilical cord blood. When older mice were injected with the protein, an inhibitor of metalloproteinases 2, dormant genes awoke and hippocampal activity increased, according to The Los Angeles Time. The mice were found to have a better performance with memory and learning tasks. The authors believe that these findings may translate to humans.
Post-surgical treatment for patients who previously received treatment for prescription or opioid misuse disorder has proven difficult, according to NPR. Healthcare providers may not be able to determine the best course of action to anesthetize patients or manage pain post-surgery for those with former drug misuse disorders, which could lead to relapse and overdose. Accessing addiction specialists after surgery may mitigate some risks associated with pain management among these patients, according to the article.
FDA Grants Accelerated Approval to Asciminib for Adult Patients With Newly Diagnosed Ph+ CML-CP